Arthritis Rheumatol: Atherosclerosis Vascular Events in multi-center SLE queues

In previouspublished articles, about 10% of SLE patients develop atherosclerosis vascular events (AVE)The study was designed to investigate the annual incidence and potential risk factors of AVE in a multi-country, multi-ethnic SLE initial queueFrom 1999 to 2017, a large sLE patient queue consisting of 33 centres was followed up annuallyBased on evidence that SLE was inactive at a TIME in AVE and that imaging or pathologically typical atherosclerosis changes and/or other atherosclerosis elsewhere, AVEs were determined to be attributed to atherosclerosisThe analysis includes descriptive statistics, the incidence of AVE per 1000 patientyears, and a single- and multi-factor relative risk regression modelOf the 1,848 patients included in the group, 1,710 were followed at least once after entering the group, for a total of 13,666 patientsOf the 1710 patients, 3.6% had 1 or more AVEs attributed to atherosclerosis, with an incident rate of 4.6 per 1,000 patients per yearIn multi-factor analysis, the lower incidence of AVE was associated with antimalarial drugs (HR: 0.54 (95% CI 0.32, 0.91), while the higher incidence of AVE was associated with past vascular events (VE) (HR: 4.00,10.30) and the body mass index (BMI) and body mass index (BMI) (HR: 2.74 ,1.04,788)Past AVE increases the risk of subsequent AVE (HR 5.42 (3.17, 9.27), p 0.001)The prevalence and incidence of AVE in this study were much lower than previously published dataThis may be related to better control of disease activity and classic risk factors